Clinical study of robotic-assisted cardiology solution reaches conclusion

Robocath, a French healthcare technology company focused on designing robotic solutions that can treat vascular diseases, has completed a clinical study of its R-One robotic assistance platform. The final patient was enrolled in October 2021. 

R-One was designed to enhance the safety of robot-assisted coronary angioplasty procedures. Results of the study, which included 62 patients across six European hospitals, will be presented in May at the EuroPCR conference in Paris.

“The conclusion of the R-Evolution study marks the end of years of hard work and investment by everyone involved and I am grateful to all of them," Philippe Bencteux, MD, Robocath president and founder, said in a prepared statement. "We are genuinely on the cusp of a new era in vascular medicine."

“Robotics is, in all likelihood, the future of interventional cardiology; there is no doubt in my mind that this study will prove that,” Jean Fajadet, MD, an interventional cardiologist at the Clinique Pasteur in Toulouse added in the same statement. “Vascular robotics now allows us to position a stent with millimeter precision and place it safely, as the robot holds and guides the instruments throughout the procedure.

Around the web

A redesigned patient-centered medical home approach focused on addressing high-value elements of care increased ED visits and had no effect on primary care spending, a new study shows.

The grants will be handed out to 45 recipients and will help hospitals deal with the continued influx of patients suffering from COVID-19.

Removing this longstanding safety standard would degrade care quality without increasing patient access, ACR CEO William Thorwarth Jr. wrote recently.  

Trimed Popup
Trimed Popup